Botulinum neurotoxin type A improves vasti muscle balance, patellar tracking, and pain in patients with chronic patellofemoral pain
Journal of Orthopaedic Research · 2023-05 · 41 (5) · 962-972
DOI: 10.1002/jor.25435 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Orthopaedic Research, online erschienen am 05.09.2022. Verfasst von Saikat Pal und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, New Jersey Institute of Technology, Newark, New Jersey, USA. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Patellofemoral Pain Syndrome, Chronic Pain. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Ipsen Biopharmaceuticals.
Abstract (Originalsprache)
The purpose of this study was to determine the effects of botulinum neurotoxin type A (BoNT‐A) on vastus lateralis:vastus medialis (VL:VM) muscle balance, patellar tracking, and pain in patients with chronic patellofemoral (PF) pain. We recruited 13 participants (9 females, 4 males) with recalcitrant PF pain who underwent ultrasound‐guided BoNT‐A injections into the distal third of the VL muscle, followed by a 6‐week home exercise program to strengthen their VM muscle. We imaged the participants in a C‐arm computed tomography (CT) scanner before and after the intervention. We calculated VL:VM ratios from CT images from a supine, nonweight‐bearing condition. We obtained patellar tilt and bisect offset values from CT images from an upright, weight‐bearing condition. We recorded functional pain scores before, immediately after, and 2–4 years after the intervention. We classified the participants into normal tracking and maltracking groups based on their patellar tilt and bisect offset values. BoNT‐A with home exercise reduced VL:VM ratio (18%; p < 0.001), patellar tilt (19%; p = 0.020), and bisect offset (5%; p = 0.025). Four participants classified as maltrackers before the intervention transitioned to normal tracking after the intervention. Functional pain scores improved immediately after the intervention (13%, p < 0.001) and remained improved at 2‐year follow‐up (12%, p = 0.011). Statement of Clinical Significance: This study provides new evidence in support of BoNT‐A for treatment of PF pain. Classification of patients under weight‐bearing conditions may identify individuals who will most benefit from a BoNT‐A treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, New Jersey Institute of Technology, Newark, New Jersey, USA.
- Division of Mechanical and Biomedical Engineering, Graduate Program in System Health Science and Engineering, Ewha Womans University, Seoul, South Korea.
- Department of Bioengineering, Stanford University, Stanford, California, USA.
- Department of Orthopaedic Surgery, Stanford University, Stanford, California, USA.
ORCID-Profile: Saikat Pal, Jang-Hwan Choi
Förderung
- Ipsen Biopharmaceuticals
Zitieren
APA
Pal, S., Choi, J. H., Delp, S. L., & Fredericson, M. (2023). Botulinum neurotoxin type A improves vasti muscle balance, patellar tracking, and pain in patients with chronic patellofemoral pain. Journal of Orthopaedic Research, 41(5), 962-972. https://doi.org/10.1002/jor.25435
Vancouver
Pal S, Choi JH, Delp SL, Fredericson M. Botulinum neurotoxin type A improves vasti muscle balance, patellar tracking, and pain in patients with chronic patellofemoral pain. Journal of Orthopaedic Research. 2023;41(5):962-972. doi:10.1002/jor.25435
BibTeX
@article{Pal2023,
author = {Pal, Saikat and Choi, Jang-Hwan and Delp, Scott L and Fredericson, Michael},
title = {Botulinum neurotoxin type A improves vasti muscle balance, patellar tracking, and pain in patients with chronic patellofemoral pain},
journal = {Journal of Orthopaedic Research},
year = {2023},
volume = {41},
number = {5},
pages = {962--972},
doi = {10.1002/jor.25435}
}
EUVIMED